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Abstract 
 
Extracellular protein misfolding and aggregation underlies many of the most serious 
amyloidoses including Alzheimer’s disease, spongiform encephalopathies and type II 
diabetes. Despite this, protein homeostasis (proteostasis) research has largely focussed on 
characterising systems that function to monitor protein conformation and concentration 
within cells. We are now starting to identify elements of corresponding systems, 
including an expanding family of secreted chaperones, which exist in the extracellular 
space. Like their intracellular counterparts, extracellular chaperones are likely to play a 
central role in systems that maintain proteostasis, however, the precise details of how 
they participate are only just emerging. It is proposed that extracellular chaperones patrol 
biological fluids for misfolded proteins and facilitate their clearance via endocytic 
receptors. Importantly, many amyloidoses are associated with dysfunction in rates of 
protein clearance. This is consistent with a model in which disruption to, or 
overwhelming of, the systems responsible for extracellular proteostasis results in the 
accumulation of pathological protein aggregates and disease. Further characterisation of 
mechanisms that maintain extracellular proteostasis will shed light on why many serious 
diseases occur and provide us with much needed strategies to combat them. 
 
 
Keywords: Protein aggregation; receptor-mediated endocytosis; clearance; proteostasis; 
Alzheimer’s disease.
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Introduction  
 
Protein homeostasis (proteostasis) refers to all those processes that collectively maintain 
the levels, structure and function of proteins in living systems. The demands placed upon 
proteostasis systems become progressively greater with increasing organismal 
complexity, and in large multicellular organisms, these demands are spread across two 
major environments, the intracellular and extracellular spaces. Both of these 
environments impose stresses upon protein structure, such as oxidative stress and 
fluctuations in temperature and pH. The extracellular space is more oxidising than inside 
cells
1
 and imposes an additional challenge to protein stability in the form of shear stress 
resulting from the continuous pumping of plasma around the body, which can induce 
protein unfolding and aggregation.
2-3
 Chaperones are key elements in the systems that 
safeguard against the effects of these stresses, and other influences that negatively impact 
upon the proteome. Chaperones selectively bind to non-native protein molecules to 
inhibit their aggregation and some chaperones are able to facilitate the correct folding of 
proteins into their native conformation.
4
 What is becoming increasingly clear is that 
chaperones also play key roles in the disposal of unfolded/misfolded proteins that are 
refractory to refolding, and that it is this function that may be especially important in 
normally protecting against serious disease.  
 
Excessive misfolding/unfolding of proteins can potentially cause pathology by a variety 
of mechanisms, including loss of biological function, toxic gain-of-function (e.g. 
cytotoxic oligomers), physical entrapment of other proteins in aggregates, and in the case 
of large deposits, disruption of tissues. The amyloidoses, and other protein misfolding 
diseases, result from dysfunctions in proteostasis that lead to an inappropriate 
accumulation of one or more proteins and associated pathology. Under these conditions, 
chaperones and other elements of proteostasis may be physically overwhelmed by the 
quantities of non-native proteins presented to the system and disease results. In the 
intracellular context, it is now well recognised that the levels of chaperones and the 
capacity of clearance mechanisms declines with age.
5
 This trend, likely to also apply in 
the extracellular context, may well account for the age-related onset of many of the 
amyloidoses and related diseases. In the future, the most effective therapies for these 
diseases will target those processes directly responsible for the underlying causation, 
rather than treating downstream consequences of this. It is striking then to note that 
despite the fact that extracellular protein misfolding and aggregation is strongly 
implicated as underpinning the onset of many of the most serious amyloidoses (Table 1), 
current understanding of those processes controlling proteostasis in the extracellular 
spaces of the body is at best rudimentary. It is only just over 10 years since the first 
abundant extracellular chaperone (clusterin) was reported
6-7
 and details of how 
extracellular chaperones protect the body from serious disease is only now beginning to 
emerge.
8-9
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Table 1. Examples of extracellular amyloid deposition and the co-localisation of 
extracellular chaperones with amyloid in disease. 
Disease 
Aggregating 
protein/peptide 
Co-localised chaperones 
Alzheimer’s disease Aβ 
Clusterin,
10
 α2-macroglobulin,
11
 
haptoglobin,
12
 apolipoprotein E,
13
 
serum amyloid P
14
 
Spongiform 
encephalopathies 
Prion Protein 
Clusterin,
15-16
 α2-macroglobulin,
17
 
apolipoprotein E,
13
 serum amyloid P
18
 
Familial British 
dementia 
ABri 
Clusterin,
19
 serum amyloid P,
20
 
apolipoprotein E 
21
 
Familial Danish 
Dementia 
ADan 
Clusterin,
22
 serum amyloid P
20
 
Down’s syndrome Aβ 
Clusterin,
23
 apolipoprotein E,
13
  
serum amyloid P
24
 
Type II Diabetes 
Human Islet Amyloid 
Peptide 
Clusterin,
25
 apolipoprotein E,
26
 
serum amyloid P
27
 
Haemodialysis-related 
amyloidosis 
β2-Microglobulin 
α2-macroglobulin,
28
  
serum amyloid P
28
 
Amyloidotic 
cardiomyopathy 
 
Transthyretin, 
Immunoglobulin light 
chain 
Clusterin
29-30
 
Systemic Amyloidosis 
Immunoglobulin light 
chain 
Clusterin,
31
 serum amyloid P,
31
 
apolipoprotein E
21
 
Icelandic Type 
HCHWA-1 
Cystatin C 
Apolipoprotein E
21
 
Myeloma-associated 
amyloidosis 
Immunoglobulin light 
chain 
Apolipoprotein E
21
 
Corneal Dystrophies Keratoepithelin Clusterin,
32
 apolipoprotein E
32
 
 
 
The expanding family of extracellular chaperones 
 
There is strong evidence supporting the existence of extracellular mechanisms to control 
proteostasis and to indicate that exposed hydrophobicity targets extracellular molecules 
for rapid clearance and intracellular degradation,
33-37
 however, the precise mechanisms by 
which this is achieved in vivo are not yet known. Exposed hydrophobicity on misfolded 
proteins is the driving force for the formation of toxic aggregates
38
 and is proposed to 
stimulate aberrant inflammation which often accompanies protein deposition in vivo.
39-40
 
Thus, the discovery of extracellular molecules that preferentially interact with misfolded 
proteins, be they secreted chaperones (discussed in detail below), receptors (e.g. 
scavenger,
41-42
 toll-like
43-44
 and MAC-1
45-46
 or elements of protease systems (e.g. tissue 
plasminogen activator)
47-48
 is extremely important. Moreover, the characterisation of how 
these different molecules interplay in order to maintain proteostasis will potentially shed 
light on why some amyloidoses occur and provide us with more informed strategies for 
combating these diseases.  
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It is well established that “holdase” chaperones are vital in targeting misfolded 
intracellular molecules for protease degradation or for repair by “foldase” chaperones. 
While normally intracellular chaperones may be present in the extracellular environment, 
their abundance is normally extremely low (e.g. Hsp70 is present in blood plasma at < 10 
ng/mL).
49
 Also, ATP which is needed to fuel intracellular protease systems and foldase 
chaperones is at least 1,000 times less concentrated outside of the cell than inside.
50
 
Therefore, the efficient processing of misfolded extracellular proteins is likely to be 
managed by abundant, normally secreted, ATP-independent mechanisms that are 
constitutively present in blood plasma, cerebrospinal fluid, interstitial fluid and all 
extracellular spaces. Three secreted glycoproteins, namely clusterin, haptoglobin and  
α2-macroglobulin (α2M) are known to have ATP-independent chaperone activity in 
vitro.
7,51-52
 These structurally unrelated proteins have the ability to stably bind misfolded 
proteins and thereby inhibit inappropriate protein–protein interactions, prevent 
aggregation, and maintain proteins in solution. All three extracellular chaperones 
demonstrate the ability to influence amyloid formation in vitro,
53-54
 and are found co-
localised with clinical amyloid deposits in vivo (Table 1). Two other secreted 
glycoproteins, apolipoprotein E (ApoE) and serum amyloid P (SAP), that are universally 
found associated with amyloid deposits are also known to influence amyloid formation in 
vitro,
55-56
 however, less is known about their ability to stabilise misfolded proteins.  
 
 
Clusterin 
 
Clusterin (also known as apolipoprotein J/ApoJ) is a highly glycosylated, heterodimeric 
protein (formed by disulfide-linked α and β subunits) of approximately 60 kDa that is 
expressed by a wide variety of tissues and found in all extracellular fluids which have 
been tested. Branched, sialic acid-rich, N-linked carbohydrates contribute 17-27% of the 
mass of mature human clusterin.
57
 This high carbohydrate content has impeded 
traditional methods for structural analysis such as x-ray crystallography, however, several 
α-helical regions are predicted by sequence analysis.
58
 It has been proposed that 
amphipathic α-helical regions on clusterin form a molten globule-like binding pocket that 
is important in mediating its binding to a diverse range of ligands.
59
 The concentrations 
of clusterin in human blood plasma and cerebral spinal fluid (CSF) are 35-105 µg/mL
60
 
and 1.2-3.6 µg/mL,
61
 respectively. Clusterin was named for its propensity to cause cell 
clustering in vitro,
62
 however, a large number of diverse biological functions have been 
proposed including roles in complement regulation,
63
 apoptosis
64
 and lipid transport.
58
 
Considering that the ligand binding profile of clusterin is extremely broad, it is plausible 
that the functions of this protein are equally far reaching. There have been many studies 
on the importance of clusterin in the pathogenesis and progression of cancer, however, 
depending on the system clusterin appears to be either pro- or anti-apoptotic.
65
 Clusterin 
is encoded by a single gene that is highly conserved across mammalian species, which 
supports that its role in vivo is of fundamental importance. Supporting a protective role 
for clusterin, it is up-regulated in experimental models of oxidative stress,
66
 shear stress,
67
 
proteotoxic stress,
68
 heat stress
69
 and upon exposure to ionizing radiation
70
 or heavy 
metals.
71
 Clusterin is also overexpressed in tissue injury and in many serious diseases in 
vivo.
72-73
 This includes up-regulation of clusterin expression in several of the amyloidoses 
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including Alzheimer’s disease,
74-75
 Down’s syndrome
76
 and diabetes,
77-78
 and also in 
aging.
65,79
 
 
Clusterin inhibits stress-induced amorphous protein aggregation by binding to exposed 
regions of hydrophobicity on non-native proteins to form soluble, high molecular weight 
complexes.
7,80-81
 This activity is similar to, but more potent than, the chaperone activity 
of intracellular small heat shock proteins (sHsps).
80
 Like sHsps, clusterin also has a 
tendency to self-aggregate into high order oligomers. Mildly acidic pH favours 
dissociation of oligomeric clusterin, thereby increasing the surface hydrophobicity of the 
molecule and in turn its chaperone activity.
82
 Exactly how clusterin is able to stably hold 
misfolded protein in extremely large yet soluble complexes (≥ 4 x 10
7
 Da) remains 
unknown,
81
 but its ability to promiscuously interact with hydrophobic ligands is believed 
to involve several amphipathic α-helices.
59
 Immunoaffinity depletion of clusterin from 
human plasma markedly increases plasma protein aggregation and precipitation after 
incubation at physiologically relevant temperature.
82
 In plasma subjected to mild shear 
stress, fibrinogen, ceruloplasmin and albumin have been identified as major endogenous 
clients for the chaperone action of clusterin,
83
 however, the available data suggests that 
clusterin preferentially binds to hydrophobic regions on proteins regardless of their 
identity. Thus, it is likely that the detection of endogenous clients in this way was biased 
towards those proteins that are relatively more abundant and relatively less stable. It has 
recently been shown that in rats, blood-borne clusterin-misfolded protein complexes are 
rapidly transported to the liver.
9
 Furthermore, the same complexes are preferentially 
recognised by fucoidin-inhibitable receptors on hepatocytes and are subsequently 
delivered to intracellular lysosome for degradation.
9
 These findings strongly support an 
important role for clusterin in the targeted delivery of misfolded protein to endocytic 
receptors for disposal, however, more studies are needed in order to fully characterise this 
pathway and understand its significance in health and disease. We have proposed that 
clusterin may be a critical element in a system designed to clear the body of misfolded 
proteins, and perhaps also proteolytic fragments generated from insoluble protein 
deposits (Figure 1). The other extracellular chaperones may play similar roles in 
protecting the body from amyloid and other diseases involving the inappropriate 
extracellular aggregation and deposition of proteins. 
 
It has been demonstrated that clusterin influences amyloid formation by a large number 
of peptides/proteins.
53,84-88
 While clusterin does not bind to native amyloidogenic proteins 
nor mature fibrils, the binding of clusterin to prefibrillar species important at the 
nucleation stage of amyloid formation inhibits their further growth.
53,84
 The ability of 
clusterin to inhibit amyloid formation is dose-dependent but not mono-phasic. At very 
low ratios of clusterin to fibril forming client protein, amyloid formation can be 
significantly increased, but decreased at higher ratios of clusterin to client protein.
53
 The 
former effect may be due to the stabilisation of structures that seed amyloid formation. 
This ratio-dependent behaviour is likely to explain why reports on the in vitro effects of 
clusterin on amyloid cytotoxicity are mixed.
53,88-89
 The results of clusterin knockout mice 
studies have further fuelled debate over whether this protein is protective or harmful. 
Supporting a protective role, clusterin knockout increases damage after heat-shock,
90
 
myosin-induced auto-immune myocarditis
91
 and post-ischemic brain injury.
92
 Moreover, 
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it has been demonstrated that clusterin knockout mice develop progressive 
glomerulopathy which is characterised by the accumulation of insoluble protein deposits 
in the kidneys.
93
 This latter result directly implicates clusterin in the clearance of 
potentially pathological aggregating proteins in vivo. In contrast, in amyloid precursor 
protein (APP) transgenic mice, clusterin knockout reduces fibrillar Aβ amyloid 
deposition and neurotoxicity.
94
 The same result has been shown for ApoE knockout, 
however, double knockout of clusterin and ApoE resulted in early disease onset and a 
marked increase in Aβ peptide levels and amyloid formation.
95
 Taken together the 
available data suggests that clusterin and ApoE work synergistically to inhibit the 
deposition of fibrillar Aβ in vivo. The mechanism(s) by which this is achieved are not yet 
known, however, the formation of complexes between Aβ and clusterin or ApoE is 
known to affect the rate by which Aβ is cleared from the brain.
96
 Of note, the ApoE 
genotype has been firmly established as a genetic risk factor for sporadic Alzheimer’s 
disease in humans.
97-98
 Much more recently, two independent genome-wide association 
studies of several thousand individuals have identified that polymorphism in clusterin is 
also a strong genetic risk factor for the same disease.
99-100
 
 
 
Haptoglobin 
 
Haptoglobin is a secreted glycoprotein that is best known for its role in haemoglobin 
binding.
101
 In humans haptoglobin is expressed as one of three major phenotypes (Hp 1-
1, Hp 1-2 and Hp 2-2) depending on the presence of two principal alleles (Hp1 and Hp2) 
which encode distinct a subunits (α
 1
 and α
 2
, respectively). Hp 1-1 consists of a disulfide-
linked (α
 1
)2β2 structure (ca. 100 kDa). However, in Hp 2-1 and Hp 2-2, an additional 
cysteine residue in the α2 chain allows the formation of a complex series of various sized 
disulfide-linked αβ polymers (ca.100 - 500 kDa). As for clusterin, there is no x-ray 
crystallography data available for haptoglobin. However, haptoglobin shares a high 
degree of homology with the chymotrypsinogen-like serine protease family
102
 and 
homology modelling has been used to predict its structure.
103
 It has been suggested that a 
large hydrophobic region adjacent to the haemoglobin-binding site is responsible for the 
chaperone activity of the protein.
104
 
 
Haptoglobin is found in most extracellular fluids and is present in human plasma and 
CSF at 0.3-2.0 mg/ml
101
 and 0.5-2 µg/ml,
105
 respectively. In addition to its role in 
haemoglobin binding, haptoglobin has also been implicated in regulation of the immune 
system
106-107
 and cathepsin B activity,
108
 and appears to have pro-angiogenic effects.
109
 
Haptoglobin is an acute phase protein and is up-regulated during infection, neoplasia, 
pregnancy, trauma, acute myocardial infarction and other inflammatory conditions.
110
 
Sequestration of haemoglobin by haptoglobin reduces the amount of free haemoglobin 
and iron available to catalyse oxidative reactions,
111
 and inhibits nitric oxide
112
 and 
prostaglandin synthesis.
113
 Thus, the binding of haptoglobin to haemoglobin is a 
biologically important protective mechanism. Haptoglobin phenotype has been examined 
for clinical relevance in a number of diseases (reviewed in 
110
), however, there is little 
reported data relating to its significance in amyloid disease. Haptoglobin phenotype is 
known to be a risk factor for cardiovascular disease in diabetes,
114-115
 although, how this 
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may relate to its chaperone activity remains unknown. One study has reported that 
haptoglobin concentrations are reduced in the CSF of patients with Alzheimer’s 
disease,
116
 however, it has also been reported that haptoglobin CSF levels are not 
significantly different between Alzheimer’s patients and normal control subjects
117
 and 
also that high serum concentrations of haptoglobin are indicative of cognitive 
impairment.
118
 It is unknown whether haptoglobin levels change during human aging, 
however in horses, foals (12 ≤ months of age) have significantly higher serum 
haptoglobin levels compared to adults.
119
    
 
Characterisation of the chaperone activity of haptoglobin is so far limited to a few 
studies. Like clusterin, all three haptoglobin phenotypes inhibit the stress-induced 
amorphous aggregation and precipitation of a wide variety of proteins in vitro.
51,120
 
However, in contrast to clusterin, lowered pH greatly reduces the chaperone activity of 
haptoglobin and this corresponds with a reduction in the affinity of haptoglobin for the 
hydrophobic dye bisANS.
51
 The available data suggest that at physiologically relevant pH 
haptoglobin is more efficient at solubilising stressed proteins that intracellular sHsps, but 
is less efficient than clusterin.
51
 Haptoglobin binds to a range of amyloid forming 
peptides/proteins and at substoichiometric ratios inhibits amyloid formation by binding to 
transient prefibrillar species.
54
 Complexation with haemoglobin reduces but does not 
abolish the ability of haptoglobin to inhibit amorphous or fibrillar protein 
aggregation.
54,104
 Haptoglobin polymorphism has been shown to influence the 
susceptibility to and/or outcome in several diseases, however, so far this does not include 
any of the amyloidoses.
121
 Aside from the co-localisation of haptoglobin with amyloid 
deposits in Alzheimer’s disease (Table 1), there have not yet been in vivo studies of the 
effect of haptoglobin on proteostasis, however, it is known that haptoglobin-haemoglobin 
complexes are preferentially recognised by the endocytic scavenger receptor CD163.
122
 
Hp is also known to bind to CD11b/CD18 integrin (Mac-1/CR3), which also binds 
denatured proteins, the iC3b fragment of complement, and the CD22 B lymphocyte 
receptor.
123
 Thus, it appears feasible that Hp might interact with one or more of these 
receptors to mediate the clearance and degradation of misfolded extracellular proteins. 
Therefore, it is tempting to speculate that the formation of complexes between 
haptoglobin and misfolded proteins may also target them for clearance via a similar 
mechanism to that implicated for clusterin-client protein complexes.  
 
 
α2M  
 
α2M is a major blood glycoprotein that is also present in most other extracellular fluids. 
α2M is a tetramer comprised of four identical subunits that form disulfide-linked dimers, 
which then non-covalently interact to give the 720 kDa tetrameric quaternary structure.
124
 
Only limited x-ray crystal data has been obtained for α2M, however, the extensive 
structural information available for human C3
125-128
 has allowed for detailed prediction of 
the location of homologous domains within α2M.
129
 α2M is predicted to contain eight 
fibronectin type-3 folded macroglobulin domains in addition to an alpha helical TED 
(thiol ester-containing) domain, a CUB (complement protein subcomponents C1r/C1s, 
urchin embryonic growth factor and bone morphogenetic protein 1) domain and a RBD 
 9 
(receptor binding domain).
127
 The concentrations of α2M in human plasma and CSF are 
1.5–2 mg/mL and 1.0–3.6 mg/mL, respectively.
130-131
 While α2M is best known for its 
role as a broad spectrum protease inhibitor,
131
 many other biological functions, including 
roles in immunomodulation and cancer progression, have been proposed.
132-136
 Similar to 
clusterin and haptoglobin, α2M has been shown to have a holdase chaperone activity 
which inhibits amorphous and fibrillar protein aggregation in vitro. Depletion of α2M 
from human plasma renders plasma proteins more susceptible to precipitation at 
physiological temperatures.
52
 At present it is not known what structural elements are 
responsible for mediating the binding of α2M to misfolded proteins. Clusterin is more 
efficient at inhibiting protein aggregation compared to α2M, however, given that α2M is 
present at very high concentration in human blood plasma, its chaperone activity is likely 
to have considerable physiological relevance. α2M retains the ability to trap proteases 
after binding to misfolded proteins and α2M-protease-misfolded protein complexes are 
recognised by LRP;
52
 this represents another potential route for the targeted disposal of 
misfolded proteins in vivo. In vitro it has already been demonstrated that α2M facilitates 
the clearance of Aβ in this way.
137
 α2M inhibits the aggregation of a number of different 
amyloid forming proteins and protects cells from amyloid-induced toxicity.
54,138
 As for 
the other extracellular chaperones, α2M does not inhibit fibril elongation or disrupt 
mature fibrils, but appears to suppress amyloid formation by interacting with transiently 
formed prefibrillar species that occur early in the aggregation process.
54
 Several studies 
have reported linkage of Alzheimer's disease with markers on chromosome 12.
139 The 
location of the α2M gene on chromosome 12 together with evidence supporting a role for 
α2M in the clearance of Aβ via LRP
137
 have encouraged many researchers to look for 
disease-associated polymorphisms in the gene, however, the findings of these studies are 
heavily debated.
140-141
 While several independent studies have reported that 
polymorphism in α2M is a genetic risk factor for Alzheimer’s disease,
142-145
 several other 
studies have failed to show an association.
143,146
 There is also vigorous debate about 
whether mutations in LRP are linked with Alzheimer’s disease. 
143,147-148
 
 
 
Other secreted molecules with reported chaperone activity 
 
In recent years in vitro chaperone activity has been described for a number of secreted 
proteins (Table 2). While it is likely that maintaining extracellular proteostasis is the 
shared role of a number of proteins, many of the proposed extracellular chaperones are 
currently poorly characterised and the physiological relevance of their chaperone activity 
remains uncertain. A decade ago it was reported that serum amyloid P (SAP; a 125 kDa 
member of the pentraxin family) has ATP-independent refolding activity in vitro,
149
 
however, since then there have been no follow on studies. The data collected showed that 
at a 10 fold molar excess, SAP increased the enzyme reactivation of heat-denatured 
lactate dehydrogenase by just 25%; this poor efficiency suggests that the refolding 
activity of SAP may not be physiologically relevant. It is striking that SAP is universally 
found located with amyloid deposits in vivo,
150-153
 particularly since its concentration in 
human plasma is relatively low. In vitro, SAP has been shown to inhibit amyloid fibril 
formation and increase the solubility of Aβ.
56
 However, SAP itself is highly resistant to 
proteases and the binding of SAP to amyloid fibrils protects them from degradation.
154
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While SAP is believed to target some of its ligands to gamma Fc receptors,
155
 it is not 
known to target amyloid for disposal in this way. Furthermore, in SAP knockout mice 
amyloid deposition is delayed suggesting that it has a pro-amyloidogenic role in vivo.
156
  
 
ApoE is a 34 kDa secreted protein that is found in human plasma at approximately 60-
120 µg/ml and in CSF at around one tenth of this concentration.
157
 In humans there are 
three common alleles of the ApoE gene designated ε2, ε3 and ε4, which result in three 
heterozygous and three homozygous genotypes.
158
 The ε4 allele of ApoE is a firmly 
established genetic risk factor for late-onset Alzheimer’s disease and the ε2 allele appears 
to be protective.
97-98
 Like clusterin and α2M, it has been demonstrated that ApoE binds to 
several different amyloid forming proteins in vitro
159-160
 and ApoE has been shown to 
influence amyloid formation in a concentration dependent-manner,
55,161
 and to promote 
clearance of Aβ in vivo,
96,162
 however, its ability to interact with amorphously 
aggregating proteins is currently unknown. The ability of ApoE to promote amyloid 
formation has encouraged some researchers to describe it as a “pathological 
chaperone”,
21
 however, like clusterin it is evident that depending on the conditions used, 
the in vitro effect of ApoE on amyloid formation can also be inhibitory. Also of interest 
is the major high density lipoprotein-associated protein ApoAI which is known to 
influence Aβ aggregation and toxicity;
163
 ApoAI has yet to be examined for a general 
chaperone activity. Common to the so-called “exchangeable apolipoproteins” (which are 
capable of moving from one lipoprotein to another) clusterin, ApoE and ApoAI contain a 
number of amphipathic helices, which mediate the binding of these proteins to lipids and 
are probably involved in their promiscuous binding to a range of other hydrophobic 
molecules.
164
 
 
It was reported that the major blood protein fibrinogen (340 kDa) has chaperone-like 
activity against thermal protein aggregation.
165
 The same research group later reported 
this activity was limited to a minor subclass of fibrinogen known as fibrinogen-420,
166
 
which contains an additional 236-residue C-terminal domain (αEC).
167
 No explanation 
was provided for why the results of experiments involving conventional fibrinogen were 
inconsistent between the two studies. The latter study showed that fibrinogen-420 was 
able to reduce the thermal aggregation of citrate synthase by around 50% when 
fibrinogen-420 and citrate synthase were present at equimolar concentrations. No further 
data was presented for the intact protein, however, recombinant αEC was shown to have 
potent holdase-type chaperone activity in a number of different assays. Clearly further 
studies of fibrinogen-420 are needed before it can be classed together with the known 
extracellular chaperones.  
 
Another plasma protein of interest in this context is albumin, the major carrier of Aβ in 
human plasma.
168
 Like the extracellular chaperones, albumin is found associated with 
amyloid deposits in vivo
169
 and has been shown to inhibit amyloid formation in vitro,
170-
171
 thus a role for this protein in amyloidosis cannot be excluded. However, compared to 
genuine chaperones, on a molar basis albumin is considerably less effective at inhibiting 
protein aggregation and for this reason is often used as a negative control protein in 
chaperone assays.
81,172-173
 Moreover, high endogenous concentrations of albumin are not 
able to prevent protein aggregation when far less abundant chaperone proteins are 
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depleted from human plasma.
51-52,82
 Thus it appears that the chaperone properties of 
albumin are very limited when compared with those of clusterin, haptoglobin and α2M. 
Several other extracellular proteins have been reported to have “chaperone-like” 
properties, including caseins, secreted protein acidic and rich in cysteine (SPARC) and 
macrophage inhibitory factor (MIF). All of these proteins have been shown to inhibit 
amorphous protein aggregation in vitro, however, the ability to inhibit amyloid fibril 
formation has only been demonstrated for caseins. 174-179 SPARC has been shown to 
inhibit collagen fibrillogenesis and is believed to play an important role in the 
remodelling of the extracellular matrix
180
; it may also act as an intracellular chaperone for 
procollagen.
181
 SPARC knockout mice develop cataract and abnormal collagen 
deposition, supporting that the ability of SPARC to act as a chaperone for collagen is 
important in vivo.
182-183
 Little is known regarding the ability of SPARC to interact with 
other client proteins, however, it has been shown that SPARC can prevent the 
aggregation of heat denatured alcohol dehydrogenase at substoichiometric 
concentrations.
179
 Similarly, macrophage inhibitory factor (MIF) has been shown to 
stabilise heat denatured malate dehydrogenase and glycogen phosphorylase b.
178
 Further 
studies of the chaperone-like activity of SPARC and MIF are needed before they can be 
classified together with clusterin, haptoglobin and α2M, which are known to act against a 
very broad range of clients.    
 
Table 2. Some less completely characterised putative extracellular chaperone 
proteins.  
Protein Reported chaperone activity 
Serum Amyloid P 
(SAP) 
- Limited ATP-independent refolding activity in vitro149 
- Inhibits amyloid fibril formation and increases the 
solubility of Aβ
56
 
- Protects amyloid fibrils from degradation.154 
- Universally found located with amyloid deposits in 
vivo
150-153
 
- In SAP knockout mice amyloid deposition is delayed156 
ApoE - Influences amyloid formation in vitro 55,161 
Fibrinogen-420 - Prevents thermal aggregation of citrate synthase166 
ApoAI - Directly interacts with amyloid precursor protein and 
inhibits Aβ aggregation and toxicity
163
 
Albumin - Increases the reactivation of chemically or thermally 
denatured enzymes
184
 
- Prevents thermal aggregation of sorbitol dehydrogenase 
and the heat induced inactivation of a number of other 
enzymes
185
 
- Binds to Aβ peptide and suppresses amyloid formation170 
Casein proteins - Prevent amorphous protein aggregation (induced by 
thermal stress or reduction) and fibril formation of a 
number of model proteins
174-177
 
- Associated with amyloid-like deposits in mammary 
tissue
186-188
 
Secreted protein - Prevents thermal aggregation of alcohol dehydrogenase 
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acidic and rich in 
cysteine (SPARC) 
in vitro
179
 
- SPARC knockout mice develop cataract and abnormal 
collagen deposition
182-183
 
Macrophage 
inhibitory factor 
(MIF) 
- Stabilises thermally denatured malate dehydrogenase and 
glycogen phosphorylase b in vitro
178
 
- Isolated by Aβ peptide affinity chromatography from rat 
brain and Alzheimer’s disease brain
189
 
 
 
The emerging importance of extracellular proteostasis in protection from amyloid 
disease  
 
In the simplest model, two processes contribute to the control of protein concentration; 
production and clearance. Therefore, the accumulation of proteins at high concentrations 
can result from two not mutually exclusive possibilities - increased synthesis or reduced 
protein disposal and degradation (Figure 2). The amyloid hypothesis of Alzheimer’s 
disease proposes that disease pathology is a direct result of an imbalance between Aβ 
production and its clearance.
190
 Indeed the causative mutations in APP and presinilins 
have been found to increase the production of the aggregation prone Aβ1−42 variants of 
the peptide in vivo.
191
 This has created immense interest in treating Alzheimer’s disease 
by targeting the production or aggregation of Aβ1−42 peptide (see 
192
 for a review of 
Alzheimer’s drug targets). Indeed, targeting aggregation is a promising strategy to treat 
amyloidoses such as those associated with transthyretin accumulation.
193
 Stabilising 
native conformations rather than targeting pre-formed oligomers or fibrils is likely to be 
more successful as all aggregate species will probably exert some detrimental effects. 
Indeed, Aβ aggregate species ranging from dimers and oligomers through to fibrils have 
been shown to be toxic.
194-196
 Reducing the amount of aggregating Aβ in Alzheimer’s 
disease can also be achieved by targeting the proteases responsible for cleaving APP such 
as α-, β- or γ-secretase. One prominent example of such a treatment are the gamma 
secretase inhibitors.
197
 The scale of investment in gamma secretase inhibitors has likely 
run in to the billions of dollars. Reduction of soluble Aβ following treatment with gamma 
secretase inhibitors looked very promising, however, the fact that APP is only one of 
several gamma-secretase substrates
198
 means that translation into the clinic has been 
problematic. Most notably, the recent Phase III clinical trial of the gamma-secretase 
inhibitor Semagacestat resulted in Eli Lilly reporting a worsening of patient outcomes 
compared to those treated with placebo and that the treatment was associated with an 
increased risk of skin cancer.
199
 However, whether these negative effects are due to loss 
of gamma secretase activity on other substrates is unknown. In addition, the first 
generation of anti-aggregation treatments for Alzheimer’s disease have been 
unsuccessful. Tramiprosate, which preferentially binds soluble Aβ and maintains it in a 
soluble form did not show clinical efficacy in a phase III study.
200
 Moreover, the highest 
concentrations used in a phase II clinical trial of another anti-aggregation drug, Scyllo-
inositol, which is thought to bind to Aβ and inhibit its aggregation
201
 have been stopped 
because of high rates of serious adverse events (including nine deaths) among patients;
202
 
the reason for these negative outcomes is unknown.  
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Most cases of Alzheimer’s disease are sporadic in nature and occur in patients who do 
not carry mutations that increase the production of Aβ1−42. Importantly, recent evidence 
suggests that it is the clearance of Aβ peptide that is impaired in sporadic forms of 
Alzheimer’s disease rather than altered production levels.
203
 The elegant study of 
Mawuenyega and colleagues shows that average production rates of Aβ do not differ 
between Alzheimer’s disease patients and controls, while the authors estimate that late 
onset Alzheimer’s disease is associated with a 30% decrease in the rate of clearance of 
both Aβ1-42 and Aβ1-40.
203
 This data is consistent with the idea that in healthy individuals 
extracellular mechanisms of proteostasis operate to provide efficient clearance of toxic 
protein species.
8,204
 There are a number of potential Alzheimer’s disease treatments that 
target the removal of Aβ via immunotherapy.
192
 However, since the role of 
neuroinflammation in Alzheimer’s disease pathology is not clear
205
 and given that 
treatment with an anti-Aβ vaccine (AN-1972)
192
 promotes a cytotoxic T cell response and 
aseptic meningoencephalitis in some patients, the use of immunotherapy in Alzheimer’s 
remains complicated. 
 
An unexplored but logical strategy to reduce Aβ levels in the brain is to exploit the 
machinery of extracellular proteostasis. However, our current understanding of these 
mechanisms is largely restricted to knowledge of a small number of extracellular 
chaperones and cell surface receptors that aid in the specific internalisation of (i) 
misfolded, aggregating proteins, or (ii) stable complexes formed between extracellular 
chaperones and misfolded proteins.
9,204
 In addition, it is also becoming clear that there are 
proteolytic systems, such as the plasminogen activator system that will recognise and 
degrade extracellular protein aggregates.
206
 Genome wide association studies of 
Alzheimer’s disease support a role for dysfunctions of extracellular clearance 
mechanisms in Aβ accumulation; these studies have strongly linked ApoE
159
 and 
clusterin
99
 to Alzheimer’s disease, in addition to a less striking linkage with α2M.
145
 All 
three of these proteins can act as extracellular chaperones (see above) and have been 
shown to bind to Aβ
159,207−208
 and to promote its clearance from the extracellular space in 
cell culture systems.
137,209-210
 Relative to control CSF, Alzheimer’s disease patient CSF is 
relatively inefficient at promoting Aβ removal in cell culture studies
211
 but this ability 
can be increased by adding physiologically relevant concentrations of clusterin, 
haptoglobin and α2M.
211
 A variety of other studies also implicate the extracellular 
chaperones in Aβ clearance. Aβ in complex with clusterin interacts with the cell surface 
receptor megalin on mouse teratocarcinoma F9 cells and promotes internalisation and 
subsequent degradation of Aβ.
209
 In addition, ApoE – Aβ complexes are internalised in 
smooth muscle primary cultures by receptor-mediated endocytosis in a low-density 
lipoprotein receptor dependant manner.
210
 Moreover, α2M-Aβ complexes are internalised 
via LRP mediated endocytosis and are subsequently degraded.
137
 Importantly, clusterin, 
α2M and ApoE have been shown to promote clearance of Aβ in vivo.
96,162,212
 The removal 
of radiolabelled Aβ from mouse brain is significantly inhibited by treatment with 
antibodies against LRP-1 and α2M.
212
 In addition, the rate of Aβ1-42 clearance from the 
mouse brain across the BBB into plasma is increased by more than 80% when it is in 
complex with clusterin and this is significantly inhibited by anti-megalin antibodies.
96
 In 
the case of ApoE, the clearance of Aβ was isoform dependant with the ApoE ε4 isoform 
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being the least efficient.
162
 Interestingly, genome wide association studies of Alzheimer’s 
disease have also identified a growing list of other genes whose function has been linked 
with endocytosis (including BIN1, ABCA7, CR1, CD2AP and PICALM).
213
 
Collectively, these data suggest that extracellular chaperones and endocytosis 
mechanisms are important for the control of Aβ turnover and that perturbations in the 
function or concentration of these in humans is likely to be detrimental. Moreover, given 
that the vast majority of Alzheimer’s disease cases are sporadic and are likely to result 
from defects in clearance rather than the production of Aβ, future therapies for 
Alzheimer’s disease should explore the specific targeting of extracellular clearance 
mechanisms.  
 
It is likely that clearance mechanisms are also important in other amyloidoses. The build 
up of β2-microglobulin in dialysis related amyloidosis is a consequence of its defective 
clearance.
214
 Renal damage can lead to a lowering of the glomerular filtration rate and 
subsequent increase in plasma β2-microglobulin concentration. While the rate of 
synthesis of β2-microglobulin does not vary between haemodialysis patients and 
controls, the clearance rates are ~20 fold lower in the former.
214
 In the case of familial 
amyloid polyneuropathy (FAP), although there is no published direct measurement 
comparing transthyretin clearance in FAP patients and controls, it is known that in 
healthy individuals the amyloidogenic variant of transthyretin ([MET30]TTR) is typically 
cleared faster than non-amyloidogenic variants.
215
 This is consistent with the presence of 
a system that recognises and rapidly removes non-native protein. The fact that this variant 
accumulates with age in FAP patients may reflect a gradual breakdown in quality control 
mechanisms. In some cases the overproduction of a protein, such as immunoglobulin 
light chain or serum amyloid A protein (SAA) in AL amyloidosis and AA amyloidosis, 
respectively, is clearly responsible for large scale amyloid deposition. However, amyloid 
deposits are not static entities or a finite endpoint and can grow or diminish in size if the 
concentration of the precursor is maintained at a high or low level, respectively (Figure 
2).
216
 AA amyloid deposits are reported to regress and patient survival is increased in 
cases where SAA levels remain low.
216
 Similarly, although amyloid burden was not 
measured, reduction of β2-microglobulin concentration in dialysis related amyloidosis 
patients improved joint pain, stiffness and ability to perform daily activities.
217
 Moreover, 
reducing the soluble immunoglobulin light chain concentration in AL amyloidosis 
patients caused reduction of amyloid deposits and improved prognosis in most but not all 
patients.
218
 Therefore, even in cases of vast protein overproduction, therapeutic strategies 
that increase clearance and help maintain the steady state concentrations of proteins at 
sub-pathological levels are likely to be of benefit. 
 
 
A new frontier in amyloid disease therapies?  
 
Current therapies for amyloidoses, are largely limited to treatments to ameliorate the 
symptoms of disease rather than directly address the underlying causes. Pre-emptive 
treatments to avoid the onset of disease are so far yet to be realised. Progress in either of 
these directions will be reliant upon advances in understanding of the cellular and 
molecular processes that underpin disease onset and progression. Alzheimer’s disease is 
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the single most prevalent and costly amyloid disease impacting upon modern society, and 
yet even here our level of understanding of the causes is limited. Some of the initial 
therapeutic strategies have focused on attempting to suppress the production and/or 
aggregation of Aβ1-42, however it has only very recently become apparent that (i) the 
level of Aβ1-42 production is the same in Alzheimer’s disease patients and healthy 
individuals, and (ii) attempts to suppress Aβ production below “normal” levels can have 
serious side effects (see above). A more “holistic” examination of the systems impacting 
upon the dynamic levels of disease-relevant proteins (see Figures 1 & 2) is likely to 
improve the chances of identifying the most appropriate therapeutic targets. In the case of 
Alzheimer’s disease and the other serious diseases associated with inappropriate 
aggregation and deposition of proteins in the extracellular space (Table 1), the largest gap 
in knowledge relates to clearance mechanisms, specifically the elements comprising these 
systems and how they function together to avoid the potentially hazardous expansion of 
individual protein pools beyond normal safe levels. The available evidence strongly 
suggests that extracellular chaperones play a pivotal role in extracellular proteostasis, and 
that a much better understanding of their interactions with both misfolded proteins and 
cell surface receptors is likely to provide the building blocks critical to design new and 
effective therapies for many of the most serious amyloidoses. 
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Figure Legends 
 
Figure 1. Proposed roles for extracellular chaperones in the maintenance of extracellular 
proteostasis. Under normal physiological conditions (A) scavenger receptors may directly 
bind misfolded proteins locally. (B) Circulating extracellular chaperones target and bind 
to misfolded proteins, maintaining their solubility and facilitating their transport to 
scavenger receptors. (C) When extracellular proteostasis is disrupted, insoluble protein 
aggregates can form giving rise to activated proteases (e.g. plasmin). Extracellular 
chaperones interact with the proteolytic fragments and facilitate their transport to 
scavenger receptors. In all cases, delivery to scavenger receptors results in the 
intracellular transport of misfolded proteins to lysosomes for degradation. Reproduced 
with permission from 
9
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Figure 2. Defects in extracellular protein homeostasis results in protein accumulation. (A) 
Under normal conditions proteins are maintained at a concentration at which is required 
for their function. The mechanisms of production and clearance are the main proteostasis 
events that control this protein pool. Proteostasis machinery must be plastic in order to 
maintain protein concentration during fluctuations in production or clearance. (B)(i) If 
protein production increases (large black arrow) in the absence of an increase in 
clearance, or (ii) protein clearance is defective (thin black arrow) this may cause an 
increase in protein concentration and promote the deposition of the specific protein as 
amyloid. 
